POMC and NR3C1-1F DNA methylation in major depressive disorder and electroconvulsive therapy

HannahB Maier, Nicole Moschny, Franziska Eberle, Kirsten Jahn, Thorsten Folsche, Rasmus Schülke, Stefan Bleich, Helge Frieling, Alexandra NeyaziPharmacopsychiatry 2022 · DOI

Abstract

Introduction Patient-tailored treatment and precision medicine is still to be established in psychiatry. Adequate indicator for treatment prediction of response are still in urgent need. Major Depressive Disorder (MDD) is one of the most disabling diseases worldwide with 30.50% of MDD patients failing to be in remission after several treatment attempts. Even with electroconvulsive therapy (ECT) remission rates fail to exceed 50%. The stress response system, and its epigenetics, seem to play a role in MDD.
BibTeX
@inproceedings{maier2022pomc,
  author = {HannahB Maier and Nicole Moschny and Franziska Eberle and Kirsten Jahn and Thorsten Folsche and Rasmus Schülke and Stefan Bleich and Helge Frieling and Alexandra Neyazi},
  title = {{POMC and NR3C1-1F DNA methylation in major depressive disorder and electroconvulsive therapy}},
  booktitle = {Pharmacopsychiatry},
  year = {2022},
  doi = {10.1055/s-0042-1757648},
}

Loading related content...

Figure